Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy

被引：0
|
作者：
Delasos, Lukas
Berube, Bryan
Nikoo, Maedeh Zokaei
Wei, Wei
Shapiro, Marc A.
Hassan, Khaled Aref
Stevenson, James
Adjei, Alex A.
Pennell, Nathan A.
机构：
[1] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH USA
[2] Cleveland Clin, Cleveland, OH USA
[3] Cleveland Clin Fdn, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8611
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC
    Cortiula, F.
    Naidoo, J.
    LUNG CANCER, 2023, 181
  • [22] The Effect of Metformin on Survival Outcomes of Advanced EGFR-mutant NSCLC Patients Treated with EGFR TKIs in Thailand
    Saichaemchan, S.
    Kanjanavithayakul, Y.
    Prasongsook, N.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S484 - S485
  • [23] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [24] Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC
    Lu, Kevin
    Woodward, Brian D.
    Boys, Joshua
    Onaitis, Mark
    Husain, Hatim
    CLINICAL LUNG CANCER, 2024, 25 (01) : e58 - e61
  • [25] Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US
    Sabari, J. K.
    Yu, H. A.
    Mahadevia, P.
    Liu, Y.
    Demirdjian, L.
    Sultan, A. A.
    Chen, Y. H.
    Wang, X.
    Passaro, A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S619 - S620
  • [26] CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
    Hui, C.
    Wakelee, H. A.
    Neal, J. W.
    Ramchandran, K. J.
    Das, M.
    Nagpal, S.
    Roy, M.
    Huang, J.
    Pollom, E.
    Myall, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E110 - E110
  • [27] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [28] OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC
    不详
    CANCER DISCOVERY, 2017, 7 (10) : 1061 - 1061
  • [29] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
  • [30] Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC
    V. Aredo, Jacqueline
    Hellyer, Jessica A.
    Neal, Joel W.
    Wakelee, Heather A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 1994 - 1998
12345